# US 2008/0187928 A1 · Methods for enhancing exercise performance

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0187928 A1
- Document ID: US20080187928A1
- Status: Published application
- Kind: A1
- Application number: 11/966,851
- Filed: 2007-12-28
- Published: 2008-08-07
- Earliest claimed: 2006-12-29
- Assignees: The Salk Institute for Biological Studies
- Inventors: Ronald M. Evans; Vihang A. Narkar; Yong-Xu Wang; Michael Downes; Ruth T. Yu
- Web page: https://patentgrep.com/patent/US20080187928A1

## CPC

- A61K 31/426: 1,3-Thiazoles
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 31/47: Quinolines; Isoquinolines
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/06: Anabolic agents (androgens A61P5/26)
- A61P 25/02: for peripheral neuropathies
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q 2600/124: Animal traits, i.e. production traits, including athletic performance or the like
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/158: Expression markers
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Disclosed herein are methods for enhancing one or more effects of exercise in a subject by administering a PPARδ agonist (e.g., GW1516) to the subject in combination with an exercise program. Also disclosed are gene expression profiles unique to the combination of agonist-induced PPARδ activation and exercise. Such profiles are useful, at least, in methods for identifying the use of performance-enhancing drugs in exercised subjects (such as, professional or athletes). Direct interactions between PPARδ and exercised-induced kinases (e.g., AMPK or its subunits, AMPK α1 and/or AMPK α2) also are disclosed. Such protein-protein interactions provide new targets for identification of useful compounds.

## Claims

### Claim 1

A method for enhancing an exercise effect in a subject, comprising
performing by a subject physical activity sufficient to produce an exercise effect; and
administering to the subject an effective amount of a PPARδ agonist, thereby enhancing the exercise effect in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject is a mammal.

### Claim 3 (depends on 2)

The method of claim 2, wherein the subject is a racing mammal.

### Claim 4 (depends on 3)

The method of claim 3, wherein the racing mammal is a horse, a dog, or a human.

### Claim 5 (depends on 1)

The method of claim 1, wherein the subject is an adult.

### Claim 6 (depends on 1)

The method of claim 1, wherein the subject is an exercise-trained subject.

### Claim 7 (depends on 1)

The method of claim 1, wherein the PPARδ agonist is GW1516.

### Claim 8 (depends on 1)

The method of claim 1, wherein the PPARδ agonist is administered on the same day(s) on which the physical activity is performed.

### Claim 9 (depends on 1)

The method of claim 1, wherein the physical activity is an aerobic exercise.

### Claim 10 (depends on 9)

The method of claim 9, wherein the aerobic exercise is running.

### Claim 11 (depends on 9)

The method of claim 9, wherein the exercise effect is improved running endurance.

### Claim 12 (depends on 11)

The method of claim 11, wherein improved running endurance is improved running distance or improved running time or a combination thereof.

### Claim 13 (depends on 1)

The method of claim 1, wherein the effective amount is from about 5 mg/kg per day to about 10 mg/kg per day in a single dose or in divided doses.

### Claim 14 (depends on 1)

The method of claim 1, wherein administration comprises oral administration, intravenous injection, intramuscular injection, or subcutaneous injection.

### Claim 15 (depends on 1)

The method of claim 1, wherein the exercise effect is increased fatty acid oxidation in at least one skeletal muscle of the subject.

### Claim 16 (depends on 1)

The method of claim 1, wherein the exercise effect is body fat reduction.

### Claim 17 (depends on 16)

The method of claim 16, wherein the body fat is white adipose tissue.

### Claim 18

A method for identifying the use of performance-enhancing substances in an exercise-trained subject comprising determining in a biological sample taken from an exercise-trained subject the expression of one or more molecules listed in Tables 2 or 4.

### Claim 19 (depends on 18)

The method of claim 18, wherein:
(i) expression is upregulated in one or more of adipose differentiation related protein; stearoyl-Coenzyme A desaturase 2; acetyl-Coenzyme A acetyltransferase 2; ATP citrate lyase; adiponectin, C1Q and collagen domain containing; diacylglycerol O-acyltransferase 2; lipase, hormone sensitive; monoglyceride lipase; resistin; CD36 antigen; fatty acid binding protein 4, adipocyte; lipoprotein lipase; microsomal glutathione S-transferase 1; GPI-anchored membrane protein 1; dual specificity phosphatase 7; homeodomain interacting protein kinase 3; insulin-like growth factor binding protein 5; protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), beta isoform; protein tyrosine phosphatase-like (proline instead of catalytic arginine); member b; CCAAT/enhancer binding protein (C/EBP), alpha; nuclear receptor subfamily 1, group D, member 2(Reverb-b); transferring; archain 1; solute carrier family 1 (neutral amino acid transporter), member 5; RIKEN cDNA 1810073N04 gene; haptoglobin; retinol binding protein 4, plasma; phosphoenolpyruvate carboxykinase 1, cytosolic; cell death-inducing DFFA-like effector c; interferon, alpha-inducible protein 27; carbonic anhydrase 3; cysteine dioxygenase 1, cytosolic; DNA segment, Chr 4, Wayne State University 53, expressed; dynein cytoplasmic 1 intermediate chain 2; Kruppel-like factor 3 (basic); thyroid hormone responsive SPOT14 homolog (Rattus); cytochrome P450, family 2, subfamily e, polypeptide 1; complement factor D (adipsin); and/or transketolase; or
(ii) expression is downregulated in one or more of gamma-glutamyl carboxylase; 3-oxoacid CoA transferase 1; solute carrier family 38, member 4; annexin A7; CD55 antigen, RIKEN cDNA 1190002H23 gene; fusion, derived from t(12;16) malignant liposarcoma (human); lysosomal membrane glycoprotein 2; and/or neighbor of Punc E11; or
(iii) a combination of (i) and (ii).

### Claim 20 (depends on 18)

The method of claim 18, wherein determining expression comprises determining protein expression, determining expression of a gene encoding the protein, or a combination thereof.

### Claim 21 (depends on 20)

The method of claim 20, comprising determining expression of a gene encoding the protein.

### Claim 22 (depends on 18)

The method of claim 18, wherein the biological sample is a skeletal muscle biopsy.

### Claim 23

A method of identifying an agent having potential to enhance exercise performance in a subject, comprising:
providing a first component comprising a PPARδ receptor or an AMPK-binding fragment thereof;
providing a second component comprising an AMP-activated protein kinase (AMPK), AMPKα1, AMPKα2, or a PPARδ-binding fragment of any thereof;
contacting the first component and the second component with at least one test agent under conditions that would permit the first component and the second component to specifically bind to each other in the absence of the at least one test agent; and
determining whether the at least one test agent affects specific binding of the first component and the second component to each other, wherein an effect on specific binding identifies the at least one test agent as an agent having potential to enhance exercise performance in a subject.

### Claim 24 (depends on 23)

The method of claim 23, further comprising providing a third component comprising a PPARδ agonist; and contacting the first component, second component, and third component.

### Claim 25 (depends on 24)

The method of claim 24, wherein the PPARδ agonist is GW1516.
